logo

Syros Pharmaceuticals (SYRS)



Trade SYRS now with
  Date
  Headline
5/2/2019 8:31:49 AM Wedbush Is Increasing Syros Pharmaceuticals (SYRS) FY19 Estimate To -1.99 From -2.29
5/2/2019 8:31:32 AM Wedbush Is Increasing Syros Pharmaceuticals (SYRS) Q4 19 Estimate To -0.46 From -0.47
5/2/2019 8:31:18 AM Wedbush Is Raising Syros Pharmaceuticals (SYRS) Q3 19 Estimate To -0.60 From -0.61
5/2/2019 8:31:05 AM Wedbush Is Increasing Syros Pharmaceuticals (SYRS) Q2 19 Estimate To -0.45 From -0.46
5/2/2019 8:30:37 AM Wedbush Reiterates Syros Pharmaceuticals (SYRS) At Outperform With $13 Price Target
4/25/2019 10:09:19 AM Wedbush Reiterates Syros Pharmaceuticals (SYRS) At Outperform With $13 Price Target
3/7/2019 7:36:42 AM Syros Q4 Net Loss $18.0 Mln Or $0.54 Per Share
1/8/2019 8:07:13 AM Cygnal Therapeutics Appoints Pearl Huang As CEO
12/7/2018 8:05:27 AM Syros Announces New Preclinical Data On SY-1365, Its First-in-class Selective Cyclin-dependent Kinase 7 Inhibitor
12/3/2018 7:17:13 AM Wedbush Reiterates Syros Pharmaceuticals (SYRS) At Outperform With $13 Price Target
11/1/2018 7:20:18 AM Syros Pharma Q3 Net Loss $15.7 Mln Or $0.47/shr Vs. Net Loss $13.8 Mln Or $0.53/shr Last Year
8/8/2018 9:54:56 AM Wedbush Is Cutting Syros Pharmaceuticals (SYRS) FY18 Rev. Estimate To 4.2 M From 10.0 M
8/8/2018 9:54:48 AM Wedbush Is Lowering Syros Pharmaceuticals (SYRS) Q4 18 Rev. Estimate To 1.8 M From 3.2 M
8/8/2018 9:54:38 AM Wedbush Is Cutting Syros Pharmaceuticals (SYRS) Q3 18 Rev. Estimate To 1.8 M From 3.2 M
8/8/2018 9:54:16 AM Wedbush Is Raising Syros Pharmaceuticals (SYRS) FY19 Estimate To -1.83 From -2.00
8/8/2018 9:53:59 AM Wedbush Is Raising Syros Pharmaceuticals (SYRS) Q3 18 Estimate To -0.44 From -0.51
8/7/2018 7:43:12 AM Syros Pharma Q2 Net Loss $14 Mln Or $0.43/shr Vs. Net Loss $13.4 Mln Or $0.52/shr Last Year